Company: LIMN
Filing Date: 2025-02-07
Form Type: 424B3
Source: 0001104659-25-010605
Chunk: 350

Company: Liminatus Pharma, Inc.
Filing Date: 2025-02-07
Form: 424B3
Chunk 350
---
 interaction between recombinant CD47 and recombinant SIRPα proteins was blocked by Hu3A5 in vitro.

•

CD47 antibody promotes phagocytosis of live tumor cells by human macrophages.

•

In vitro phagocytosis assay demonstrated that human macrophages promoted the uptake of live tumor cells in the presence of as low as > 0.1 micro grams/ml of CD47 mAb.

•

Exclusive blockade of human CD47 on tumor cells with Hu3A5 in combination with check-point inhibitors induces a limited synergistic suppression of tumor growth.

•

To assess how effectively CD47 blockade enhances anti-tumor responses, hCD47-expressing MC38 tumor cells were subcutaneously engrafted into normal C57BL/6 mice, and anti-human CD47 monoclonal antibodies were injected to specifically block the function of the hCD47 protein on tumor cells, allowing evaluation of the resulting increase in anti-tumor effects.

•

This induced moderate delayed tumor growth.

•

However, in combination with anti-PD-L1 and anti-TIGIT check-point inhibitors significant synergistic activity was observed where tumor growth was regressed and most of the mice became tumor-free.

•

Global blockade of human CD47 on tumor and immune cells induces significant reduction of tumor growth.

•

Investigated whether global effects of CD47 blockade would be beneficial if all cells including immune cells were expressing human CD47.

•

Instillation of Hu3A5 alone to C57BL/6-hCD47/hSIRPα knock-in mice engrafted with MC38- hCD47 tumor cells suppressed tumor growth.

<div align='center'>189</div>

TABLE OF CONTENTS

•

When Hu3A5 treatment was combined with anti-mPD-1 mAb, tumor-free mice were generated.

**New Aspects of the CD47 Asset and Expanded Indications**

•

#### Chronic Inflammation
: Hu3A5, an anti-CD47 antibody, plays a unique role in helping immune cells called macrophages develop and survive in the body. These cells are critical in fighting disease. IBA101 not only promotes the formation of these macrophages but also increases the number of a special type, called M1 macrophages, that actively destroy harmful cells.

•

#### Reducing Chronic Inflammation
: As we age, our body becomes less effective at clearing out dead cells, leading to a buildup that contributes to chronic inflammation and diseases such as atherosclerosis (